These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31899794)

  • 1. Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia.
    Arezes J; Foy N; McHugh K; Quinkert D; Benard S; Sawant A; Frost JN; Armitage AE; Pasricha SR; Lim PJ; Tam MS; Lavallie E; Pittman DD; Cunningham O; Lambert M; Murphy JE; Draper SJ; Jasuja R; Drakesmith H
    Blood; 2020 Feb; 135(8):547-557. PubMed ID: 31899794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythroferrone inhibits the induction of hepcidin by BMP6.
    Arezes J; Foy N; McHugh K; Sawant A; Quinkert D; Terraube V; Brinth A; Tam M; LaVallie ER; Taylor S; Armitage AE; Pasricha SR; Cunningham O; Lambert M; Draper SJ; Jasuja R; Drakesmith H
    Blood; 2018 Oct; 132(14):1473-1477. PubMed ID: 30097509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.
    Kautz L; Jung G; Du X; Gabayan V; Chapman J; Nasoff M; Nemeth E; Ganz T
    Blood; 2015 Oct; 126(17):2031-7. PubMed ID: 26276665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of β-thalassemia.
    Olivera J; Zhang V; Nemeth E; Ganz T
    Blood Adv; 2023 Jul; 7(14):3339-3349. PubMed ID: 36995275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hepcidin regulator erythroferrone is a new member of the erythropoiesis-iron-bone circuitry.
    Castro-Mollo M; Gera S; Ruiz-Martinez M; Feola M; Gumerova A; Planoutene M; Clementelli C; Sangkhae V; Casu C; Kim SM; Ostland V; Han H; Nemeth E; Fleming R; Rivella S; Lizneva D; Yuen T; Zaidi M; Ginzburg Y
    Elife; 2021 May; 10():. PubMed ID: 34002695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of erythroferrone structural domains relevant to its iron-regulatory function.
    Srole DN; Jung G; Waring AJ; Nemeth E; Ganz T
    J Biol Chem; 2023 Dec; 299(12):105374. PubMed ID: 37866631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythroferrone contributes to recovery from anemia of inflammation.
    Kautz L; Jung G; Nemeth E; Ganz T
    Blood; 2014 Oct; 124(16):2569-74. PubMed ID: 25193872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of erythroferrone suppression by transfusion on the erythropoietin-erythroferrone-hepcidin axis in transfusion-dependent thalassaemia: A pre-post cohort study.
    Zaman BA; Rasool SO; Abdo JM
    Br J Haematol; 2023 May; 201(3):547-551. PubMed ID: 36535905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EPO-dependent induction of erythroferrone drives hepcidin suppression and systematic iron absorption under phenylhydrazine-induced hemolytic anemia.
    Jiang X; Gao M; Chen Y; Liu J; Qi S; Ma J; Zhang Z; Xu Y
    Blood Cells Mol Dis; 2016 May; 58():45-51. PubMed ID: 27067488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of erythroferrone as an erythroid regulator of iron metabolism.
    Kautz L; Jung G; Valore EV; Rivella S; Nemeth E; Ganz T
    Nat Genet; 2014 Jul; 46(7):678-84. PubMed ID: 24880340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythroferrone structure, function, and physiology: Iron homeostasis and beyond.
    Srole DN; Ganz T
    J Cell Physiol; 2021 Jul; 236(7):4888-4901. PubMed ID: 33372284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin's inhibiting impact on hepcidin expression occurs indirectly.
    Gammella E; Diaz V; Recalcati S; Buratti P; Samaja M; Dey S; Noguchi CT; Gassmann M; Cairo G
    Am J Physiol Regul Integr Comp Physiol; 2015 Feb; 308(4):R330-5. PubMed ID: 25519735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythroid overproduction of erythroferrone causes iron overload and developmental abnormalities in mice.
    Coffey R; Jung G; Olivera JD; Karin G; Pereira RC; Nemeth E; Ganz T
    Blood; 2022 Jan; 139(3):439-451. PubMed ID: 34614145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased hepcidin in transferrin-treated thalassemic mice correlates with increased liver BMP2 expression and decreased hepatocyte ERK activation.
    Chen H; Choesang T; Li H; Sun S; Pham P; Bao W; Feola M; Westerman M; Li G; Follenzi A; Blanc L; Rivella S; Fleming RE; Ginzburg YZ
    Haematologica; 2016 Mar; 101(3):297-308. PubMed ID: 26635037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoassay for human serum erythroferrone.
    Ganz T; Jung G; Naeim A; Ginzburg Y; Pakbaz Z; Walter PB; Kautz L; Nemeth E
    Blood; 2017 Sep; 130(10):1243-1246. PubMed ID: 28739636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice.
    Nai A; Rubio A; Campanella A; Gourbeyre O; Artuso I; Bordini J; Gineste A; Latour C; Besson-Fournier C; Lin HY; Coppin H; Roth MP; Camaschella C; Silvestri L; Meynard D
    Blood; 2016 May; 127(19):2327-36. PubMed ID: 26755707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietic regulators of iron metabolism.
    Ganz T
    Free Radic Biol Med; 2019 Mar; 133():69-74. PubMed ID: 29981834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant.
    Pirotte M; Fillet M; Seidel L; Jaspers A; Baron F; Beguin Y
    Am J Hematol; 2021 Oct; 96(10):1275-1286. PubMed ID: 34310730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between growth differentiation factor-15, erythroferrone, and iron status in thalassemic patients.
    Youssry I; Samy RM; AbdelMohsen M; Salama NM
    Pediatr Res; 2024 Mar; 95(4):1095-1100. PubMed ID: 37464096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythroferrone is not required for the glucoregulatory and hematologic effects of chronic erythropoietin treatment in mice.
    Coffey R; Sardo U; Kautz L; Gabayan V; Nemeth E; Ganz T
    Physiol Rep; 2018 Sep; 6(19):e13890. PubMed ID: 30315639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.